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UBAT GENERIK: PERSEPSI PENGAMAL  PERUBATAN,AHLI FARMASI,
PENGGUNA, PELAJAR TAHUN AKHIR JURUSAN PERUBATAN DAN
FARMASI DI IRAQ
ABSTRAK
Ubat-ubatan generik memberikan suatu peluang penjimatan dalam perbelanjaan
penjagaan kesihatan bagi pihak kerajaan dan juga para pengguna.  Dalam konteks ini,
tiada kajian dijalankan di Iraq berhubung persepsi dalam kalangan doktor, ahli farmasi,
pengguna serta bakal pengamal perubatan (seperti pelajar perubatan dan farmasi)
tentang pempreskripsian, penukar-gantian serta penggunaan ubat-ubatan generik.
Justeru, tesis ini bermatlamat untuk mengkaji persepsi serta pengetahuan yang ada pada
pengamal perubatan, farmasi serta para pengguna megenai kualiti penggunaan ubat-
ubatan generik di Iraq. Dalam usaha mencapai matlamat ini, kaedah kualitatif
digunakan.
Sepuluh orang doktor telah ditemu bual. Analisis daripada kandungan temu bual
mengenal pasti tujuh (7) tema utama: amalan mempreskrib ubat, pengetahuan tentang
kesamaan terapeutik daripada ubat-ubatan generik, penerimaan pesakit terhadap ubat-
ubatan generik, ubat-ubatan tiruan, sumber maklumat tentang drug/ubat serta pengaruh
iklan drug/ubat terhadap pilihan ubat, amalan menukar-ganti jenama oleh ahli farmasi
komuniti, serta strategi  untuk meningkatkan penggunaan ubat-ubatan generik.
Sepuluh orang ahli farmasi turut ditemu bual. Dapatan temu bual mengenal pasti lima
(5) tema utama: amalan menukar-ganti ubat generik, pengetahuan tentang perubatan
generik, kualiti dan keselamatan ubat-ubatan generik, didikan pesakit oleh ahli farmasi
xxii
tentang ubat-ubatan generik dan strategi untuk meningkatkan kegunaan ubat-ubatan
generik.
Seramai empat belas (14) orang pengguna ditemu bual untuk meninjau pendapat mereka
tentang isu-isu berkaitan penggunaan ubat-ubatan generik. Analisis daripada temu bual
mengenal pasti lima (5) tema utama: pemahaman istilah  ‘‘ubat-ubatan generik,’’
keutamaan terhadap ubat-ubatan generik,  penolakan terhadap ubat-ubatan generik,
menukar-ganti generik, dan mendidik pengguna tentang penggunaan ubat-ubatan
generik.
Berdasarkan natijah kajian yang dijalankan dalam bab 3, 4 dan 5 tesis ini, terutamanya
kekurangan pengetahuan yang ketara dalam kalangan doktor dan ahli farmasi, maka
pengetahuan dan persepsi tentang ubat-ubat generik ditinjau dalam kalangan bakal
pengamal perubatan dan farmasi di beberapa buah universiti di Iraq. Untuk kajian ini,
dua (2) soal selidik dijalankan. Bab 6 dan 7 mengutarakan metodologi dan dapatan
kajian bagi dua (2) kajian ini.  Analisis bagi respons daripada kedua-dua kumpulan
menunjukkan bahawa terdapatnya kekurangan pengetahuan tentang ubat-ubatan generik,
terutamanya dari aspek kesamaan biologi. Sebagai kesimpulan, tesis ini menonjolkan
tentang kewujudan penghalang dalam penggunaan ubat-ubatan generik di Iraq, dari kaca
mata doktor, ahli farmasi dan pengguna. Dalam usaha menangani masalah ini, tindakan
perlu digarap untuk meningkatkan keyakinan tentang ubat-ubatan generik dalam
kalangan pengamal penjagaan kesihatan. Hal ini boleh dicapai dengan memasukkan
suatu silibus baru yang sesuai di peringkat ijazah pertama, yang menjelaskan tentang
kesamaan biologi, keselamatan dan keefisienan ubat-ubatan generik.
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GENERIC MEDICINES: PERCEPTIONS OF PHYSICIANS, PHARMACISTS,
CONSUMERS, FINAL YEAR MEDICAL AND PHARMACY STUDENTS IN
IRAQ
ABSTRACT
Generic medicines provide an opportunity for major savings in health care expenditure
to both government and consumers Within this context, no studies have been conducted
in Iraq regarding the perceptions held by physicians, pharmacists, consumers and future
practitioners such as medical and pharmacy students towards the prescribing,
substitution, and use of generic medicines Therefore, the aims of this thesis were to
investigate perceptions and knowledge held by both the healthcare providers and
consumers toward the quality use of generic medicines in Iraq. In order to reach these
aims, qualitative methods were used.
Ten physicians were interviewed. Thematic content analysis of the interviews identified
seven major themes: medicine prescribing practices, knowledge of therapeutic
equivalency of generic medicines, patients’ acceptance of generic medicines, counterfeit
medicines, source of information on medicines and the influence of drug advertising on
the choice of medicine, brand substitution practices by community pharmacists, and
strategies to improve the usefulness of generic medicines.
A total of ten pharmacists were also interviewed. Five major themes emerged: generic
medicines substitution practices, knowledge about generic medication, quality and safety
of generic medicines, patient education by pharmacists regarding generic medicines and
strategies to improve generic medicine utility.
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A total of fourteen consumers were interviewed in order to explore their opinion towards
issues related to generic medicines use. Thematic analysis of the interviews identified
five major themes: understanding of the term ‘‘generic medicine,’’ preference for
generic medicine, refusal of generic medicine, generic substitution, and educating the
consumers on the use of generic medicines.
Based on the outcomes of the studies conducted in chapter 3, 4 and 5 of this thesis,
particularly the apparent knowledge deficits of physicians and pharmacists, the
knowledge and perceptions of generic medicines were explored among future medical
and pharmacy practitioners in several universities in Iraq. For these studies, two
questionnaire surveys were conducted. Chapter 6 and 7 of this thesis present the
methodology and the study findings for these two surveys. Analysis of the Responses for
both groups indicated that there is also a lack in knowledge regarding generic medicines,
especially on the aspects of bioequivalence. In conclusion, this thesis highlights the
existing barriers to the usage of generic medicines in Iraq from the points of view of
physicians, pharmacists and consumers. In order to overcome these barriers, actions are
needed to elevate confidence in generic medicines among healthcare practitioners. This
can be achieved by providing appropriate topics at the undergraduate level, clarifying
bioequivalence, safety and efficacy of generic medicines which appears to be currently
lacking.
1CHAPTER ONE: GENERAL INTRODUCTION
21.1 Introduction
The increasing price of medicine is a phenomenon that affects all countries across the
world (Birkett et al., 2001; Dickson, 1992; Donelan et al., 1999; Ess et al., 2003;
Kanavos, 1999; Ping et al., 2008; Shafie and Hassali, 2008). Using low cost generic
medicines is one of the mechanisms undertaken by many health policy makers
around the world in order to alleviate this problem (King and Kanavos, 2002a; Laing
et al., 2001; Moulds, 1992; Nilsson and Melander, 2000; Smeaton, 2000; Tatchell,
2003).
Innovator medicines are more expensive than generic medicines. Generally, generic
brands cost between 30-75% less than innovator brands (Carroll, 1995; Karim et al.,
1996b; Lieberman, 1986; Lofgren, 2004a; Yarnall, 1994). Two reasons for this lower
cost are, firstly, that generic medicine producers do not need to spend huge
investment on research and development and marketing of a new drug entity
(Kirking and Ascione, 2001; Kirking et al., 2001a; Nuss et al., 2004; Weaver, 1989),
and the second reason is competition; when a number of manufacturers produce the
same generic medicine, competition among these manufacturers can drive the price
down (Lofgren, 2004a; Lofgren and Boer, 2004; McGavock, 2001a; Stevens et al.,
1993).
1.2 Definition of generic medicines
The term ‘generic medicine’ may be defined in different ways. It can mean a product
marketed under the drug’s approved international non-proprietary name (INN), or it
can also mean a product marketed under a different brand (proprietary) name. The
World Health Organization (WHO) defines ‘generic medicine’ as ‘a pharmaceutical
product, usually intended to be interchangeable with the innovator product, marketed
after the expiry of patent or other exclusively right’(WHO, 2005b). In some
3countries, they may be marketed in dosage forms and/or strengths different from that
of the innovator products (Staff and Salud, 2004).
According to the European Generic Medicines Association (EGA), a generic
medicine is defined as ‘a medicinal product which has the same qualitative and
quantitative composition in active substances and the same pharmaceutical form as
the reference medicinal product, and whose bio-equivalence with the reference
medicinal product has been demonstrated by appropriate bio-availability studies’
(Donovan, 2003). A generic medicine is marketed in agreement with the patent law
and is recognized either by its own brand name or by its internationally approved
proprietary scientific name. A generic medicine is of the same efficacy, safety and
quality as the original brand name product and undergoes rigorous testing before it is
licensed and given market approval (Bongers and Carradinha, 2009).
In the United States, the Food and Drug Administration (FDA), which is an
American organisation responsible for registering and marketing authorisation for
medicinal products, defines generic medicine as ‘a medicine that is identical, or
bioequivalent, to a brand name medicine in dosage form, safety, strength, route of
administration, quality, performance characteristics, and intended use’ (USFDA,
2002).The Therapeutic Good Administration (TGA), which is the regulatory body
for registering and licensing medical products in Australia, defines generic medicine
as ‘medicine which has the same qualitative and quantitative composition in term of
active principles, same pharmaceutical form and bioavailability have been
carried’(TGA, 1994). In terms of basic generalisation, generic medicines should not
use a commercial brand name when marketing, but use international non-proprietary
name (INN), in practice, generics can be categorically classified as branded generics,
4which means copies of pharmaceutical specialties with their own brand, semi-
branded generics, which means products marketed only under the INN followed by
the name of the manufacturer, and unbranded generics, which are medicines
marketed under the INN (Garattini and Tediosi, 2000).
1.3 The naming process of medication
Each pharmaceutical substance is specified by an international non-proprietary name
(INN) or a generic name (Staff and Salud, 2004). Physicians and pharmacists use the
generic name commonly and when a new drug is ready to be marketed the generic
name is usually created (Gundersen, 1998). International non-proprietary names are
generated by the World Health Organization (WHO) for all pharmaceuticals
globally, using a procedure adopted by the executive board of the WHO (Staff and
Salud, 2004). Each INN is a unique name that is internationally recognised and is
public property (WHO, 2003). An important feature of the INN system is that the
names pharmacologically related substances demonstrate their relationship by using
a common ‘stem’, as shown in Table 2.1. This allows health care experts dealing
with pharmaceutical products to recognise that the substance belongs to a specific
group of substances with similar pharmacological activities (Staff and Salud, 2004).
Table 1.1 Generic names of common WHO approved stems
Stem Class of drug Generic name
-olol Β-adrenoreceptor antagonists metoprolol, atenolol
-azepam Benzodiazepine family diazepam,clonazepam
-vir Antiviral agents acyclovir
-cillin penicillin amoxycillin
-bendazole Antihelmintics (thiabendazole) albendazole
-oxetine Antidepressants fluoxetine
5The company that holds the patent for the drug can only produce and sell the brand
name medication, usually on the basis that it can be recognised, pronounced and
remembered by health experts and members of the public (Helen, 2009). The
chemical name of a medication is a scientific name based on the chemical structure
of the compound and this name may not be used to identify the drug under clinical
situations (Kenagy and Stein, 2001).
1.4 Generic medicines in international markets
The spread of generic medicines is different in different international markets and
this variation is due to the differences in generic medicine policies in the respective
countries. Simoens and De Coster (2006) conducted a study to underline the need for
generic medicines markets development and the potential savings that can be
achieved from the substitution of innovator medicine with its generic counterpart in a
number of countries for which data were available. Underlining on the off-patent
market, the top ten medicines were picked by the expenditure on innovator medicines
in 2004. As these medicines showed the top expenditure on innovator medicines,
they would be expected to make the biggest potential savings from generic
substitutions. This study showed the savings that can be made if innovator medicines
are replaced by generic medicines. Tables 2.2-4 show the top 10 active substances
for Austria, France and the UK (Simoens and De Coster, 2006) .
6Table 1.2 Potential savings from increased generic substitutions in Austria, 2004
No Active substance Public expenditure onoriginator medicines(£)
Savings from generic
substitutions(£)
1 lisinopril 33,545,548 7,973,247
2 ramipril 26,715,264 11,717,770
3 ciclosporin 22,456,438 3,545,505
4 amlodipine 22,379,694 3,701,259
5 metoprolol 22,017,335 9,580,570
6 carvedilol 21,043,749 2,998,096
7 pravastatin 19,565,709 5,364,850
8 lamotrigine 17,006,227 5,539,110
9 enalapril 16,588,539 2,183,517
10 omeprazole 16,292,170 5,358,914
Total 217,610,673 57,962,838 (27%)
Table 1.3 Potential savings from increased generic substitution in France, 2004
No Active substance Public expenditure onoriginator medicines(£)
Savings from generic
substitutions(£)
1 omeprazole 446,515,016 117,723,086
2 paracetamol 145,522,610 23,838,883
3 paroxetine 137,898,121 45,042,899
4 ethinylestradiol 137,520,042 101,370,687
5 bisoprolol 135,870,312 60,368,156
6 hydrochlorothiazide 115,174,757 41,624,759
7 citalopram 101,443,283 38,817,197
8 trimetazidine 100,035,279 35,760,821
9 fenofibrate 97,599,601 38,537,643
10 gliclazide 92,798,116 22,206,603
Total 1,510,377,137 525,290,734 (35%)
7Table 1.4 Potential savings from increased generic substitution in United
Kingdom, 2004
No Active substance Public expenditure onoriginator medicines(£)
Savings from generic
substitutions(£)
1 pravastatin 173,926,201 1,827,32
2 doxazosin 167,861,096 120,582,878
3 beclomethasone 141,198,568 8,721,002
4 simvastatin 130,721,082 36,535,810
5 nifedipine 93,826,729 40,906,097
6 budesonide 88,848,854 30,632,531
7 omeprazole 79,995,288 28,369,791
8 fentanyl 73,644,518 67,750,188
9 gabapentin 60,788,304 1,526,222
10 paroxetine 59,976,234 12,993,094
Total 1,070,786,874 349,844,935 (33%)
These tables indicate that an increased substitution of generic for originator
medicines could yield substantial savings for the top 10 active substances when
considering the expenditure on originator medicines.
Sheehan (2002) stated that generics made up around 47 % of all prescriptions filled
in the UK in 2001; however, it all represented 18 % of the total consumer spending
on prescription drugs. Table 2.5 shows shares of generics in the prescription
medicine market in selected countries in 2001 (Sheehan and Sweeny, 2002). King
and Kanavos (2002) observed that the rate of generic penetration, when measured as
a percentage of total spending on pharmaceuticals, has a lower percentage than the
percentage of sales volume.  This is due to the low prices of generic medicines when
compared to originator products (King and Kanavos, 2002a).
8Table 1.5 Shares of generics in the prescription medicine market in selected
countries in 2001
Country Share of generics in prescription medicine market in 2001 (%)
By number of scripts By value
USA 45 8.4
Australia 18.9 9.6
UK 47 18
Germany 40 28
Denmark 60 35
1.5 Bioequivalence and bioequivalence testing
Generic medicines are often substituted for innovator medicines by pharmacists in an
effort to decrease the cost of medicines. Generic substitution is allowed and
encouraged in most cases, provided that the generic formulation is accepted as
therapeutically equivalent to the innovator formulation by the FDA (Balthasar,
1999).
Generally, before a new generic formulation of an innovator medicine can be
marketed, the pharmaceutical manufacturer must prove that its action will be
essentially the same as the innovator formulation. The purpose of testing a generic
medicine is not to demonstrate the clinical usefulness of the drug but to ensure that
the generic medicine has the same relative bioavailability and bioequivalence to the
innovator product (Pearce et al., 2004).
The term ‘bioavailability’ is defined as ‘the degree to which, or the rate at which, a
medication or other substance is absorbed or becomes available at the targeted place
in the body’ (Pearce et al., 2004). Bioavailability can be affected by inactive
ingredients in the medicine, such as additives that prevent the medication from
dissolving in the stomach (Purse 2006).
9‘Bioequivalence’ is defined as ‘the rate and extent of absorption of the test drug that
does not show a significant difference from the rate and extent of absorption of the
reference drug when administered at the same molar dose of the therapeutic
ingredient under similar experimental conditions in either a single dose or multiple
doses’ or ‘the extent of absorption of the test drug does not show a significant
difference from the extent of absorption of the reference drug when administered at
the same molar dose of the therapeutic ingredient under similar experimental
conditions in either a single dose or multiple doses and the difference from the
reference drug in the rate of absorption of the drug is intentional, is reflected in its
proposed labelling, is not essential to the attainment of effective body drug
concentrations on chronic use, and is considered medically insignificant for the drug’
(Balthasar, 1999). The term ‘pharmaceutical equivalents’ refers to drug products that
contain identical amounts of identical active drug ingredients, that is, the same salt or
ester of the same therapeutic moiety, in identical dosage forms, but not necessarily
containing the same inactive ingredients (Birkett, 2003; Nation and Sansom, 1994;
TGA, 2002). Drug products are considered to be ‘therapeutic equivalents’ only ‘if
they are pharmaceutical equivalents and they can be expected to have the same
clinical effect and safety profile when administered to patients under the conditions
specified in the labelling (Balthasar, 1999; Leslie, 2002).
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1.5.1 Determining bioequivalence
The typical design employed in bioequivalence studies is the two-treatment, two-
period crossover design (Figure 2.1). In this design, subjects are randomly separated
into two groups of same numbers. In the first study period, the innovator formulation
is administered to group ‘A’, and the test formulation is administered to group ‘B’.
Cross-over design is used in the second period of the study after a separated washout
period which is designed to be of a sufficient duration to allow elimination of the
drug administered in the first period. The subjects are split into two groups to let
recognition of ‘period’ or ‘sequence’ effects in the study results (Balthasar, 1999).
Figure 1.1 Schematic representation of the standard two-treatment crossover   study design
commonly employed in bioequivalence trials
This procedure is usually carried out by calculating a 90% confidence interval that is
constructed around the ratio of the test and reference drugs by means of two one-
sided test procedures. To show bioequivalence, 90% confidence interval limits are
required in the range of 80-125% based upon a logarithm of transformed AUC and
Cmax data. This is commonly referred to as 80% / 125% ‘goalposts’ for the average
bioequivalence criterion, and has been adopted by most of the drug regulatory bodies
throughout the world (Dentali et al., 2011; Meredith, 2003; USFDA, 2009).
11
1.6 Iraq: A Historical background
Iraq lies in the Middle East bordering Turkey, 352 km; Jordan, 181 km; Syria, 605
km; Kuwait, 240 km; Saudi Arabia, 814 km; and Iran, 1458 km (Harris, 2007). Iraq’s
capital city is Baghdad and it is located in the centre of the country. Al-Basra in the
south and Mosul in the north are other major cities (Harris et al., 2007).
Figure 1.2: Map of Iraq
Iraq’s territory constitutes of four major regions: desert in the western and south
western parts, rolling uplands surrounded by the rivers Tigris and the Euphrates,
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mountains in the northern and north eastern parts, and alluvial plains in the central
and south eastern parts through which the two rivers flow (WHO, 2006).
Iraq’s area varies in different citations as between 433,970 square kilometers and
437,393 square kilometers. However, the Iraqi official statistical reports sums up the
area of the country as 438,446 square kilometers (WHO, 2006).
Estimates put the population of Iraq as 27.1 million. According to the survey done in
1977, the population was 12 million and this number increased in 1987 to reach 16.3
million. In the 1997’s survey, the population was found to be 22 million (almost
double the number of that of that in 1977). A 3% overall population growth has been
estimated during the period of 1987-1997. As a follow-up to the world summit for
children, a national report was issued noting that the total population had reached
23.1 million by the year 2000 with an estimated growth rate at 2.94 million (WHO,
2005a).
“Males constitute 50.2% of the population, children below 5 years of age constitute
about 17% of the population, children under 15 almost 40.5 percent, and those of
adolescent age (10-19 years) form about 23% of the population. Women at
childbearing age constitute about 22% of the population. Those who are 60 years old
and 65 years and above form 3.8% and 2.8 % of the total population, respectively.
More than 24% of the population lives in Baghdad, 9.5% in Mosul, 6.6 % in Basra,
5.2% in Erbil, and 6.3% in Sulaimaniya. Two thirds of the population (67.1 %) live
in urban areas and one third in rural areas. Around 97% of the population are
Muslims. The remaining 3% is made up of Christians and other religious groups. The
Kurds, descendants of Indo-European tribes who settled in Iraq in the 2nd century
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B.C., make up 15-20 % of the population. Arabic is the official language, but
Kurdish, Assyrian, and Armenian are also spoken (WHO, 2005a).
Regarding the climate, Iraq in summer has a constant north-westerly wind (shamal),
while in winter a strong south-easterly air current (sharqi) develops. The highly hot
and dry summers start from May to October, and during the hottest time of the day-
often reaching 49°C in the shade. Winters, starting from December to March, are
humid and moderately cold, with temperatures averaging about 10°C. Normally, no
rain falls from the end of May to the end of September. With annual rainfall of less
than 38 cm (15 in), agriculture is dependent on irrigation (Iraq, 2011).
1.6.1 Overview of Iraqi health care system
In the early 1920s, the Iraqi modern health system saw its first light. Iraq’s first
government established the Ministry of Health (MOH), which after a couple of years
became a part of the Ministry of Interior until 1939, when it became a part of the
Ministry of Social Affairs. This continued until 1952, when a new Ministry of Health
was re-established and continues to the recent time. Since the early decades of the
20th century, the MOH went through various organizational structures. The latest
structure was adopted after the recent war in 2003, and is meant to see further
modifications.
Providing the Iraqi people with health care is the responsibility of the MOH. After
the 2003 war, the MOH started to receive its funding from the Ministry of Finance.
However, the given funds are barely enough to cover staff members’ salaries with
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some minor funds for the purpose of covering other recurrent expenses (Izdihar,
2006).
Public Clinics, is the name of a specialist directorate in the MOH providing the
public with curative care at subsidised prices for a period of three hours a day in the
afternoon, outside the official working hours of public facilities. The directorate of
Public Clinics utilizes the buildings of many primary health care centres in order to
provide these services (Izdihar, 2007).These clinics play a great role in the delivery
of drugs to patients with chronic diseases, through a drug card carried by the patients,
on a monthly basis. These clinics are completely independent facilities and cover all
of their expenses and payments through patients’ capitation fees. Some of their
profits might be forwarded to the Ministry of Finance. The clinics recruit their staff
independently either from MOH staff or retired or private practitioners. Private
hospitals are licensed and monitored by the MOH. Private clinics and pharmacies are
supposed to be licensed by medical syndicates.
The Ministry of Health owns a trading company called KIMADIA. Established in
1966, two thirds of KIMADIA’s work involves the importation, storage and
distribution of drugs and medicine supplies. The KIMADIA system controls all the
imported medicines into Iraq (both public and private). Random samples are taken
from each batch and are sent for testing to the National Drug Quality Control
Laboratories (NDQCL). Once the batch passes the test, the NDQCL informs the
department of planning in MOH/KIMADIA in order to prepare for the planning of
distributing this item to the governorate’s Directorates of Health (DOHs).
15
KIMADIA
Private sectorPublic sector
NDQCL
Governorate DOH
(pharmacy department)
Hospital
PHCS
Public
clinic
Pharmacies
Patients
Locally produced
drugs Imported Medical items
Health
insurance
centers ( rural
area)
Subsidize price or
free
Figure 1.3: The Stages of MOH/KIMADIA Drug Distribution System
For more than two decades, KIMADIA has been the only authorized body by law to
manage, plan, select, quantify, procure, store and distribute medicines and medical
equipment. In 1989, it was estimated that 70% of the drugs were imported. The
Samara Drugs Industries (SDI) covers the remaining 30%, counting 160 different
dosages and forms.
Public and semi public sectors dominated the supply of medicines until the year
1994.Most of drugs (90%) were made available by using the public budget and were
allocated to the public and semi-public sectors. According to Iraqi law, the
KIMADIA system must market all drugs. After 1994, the private practice has been
assisted by the Iraqi government and 700 new pharmacies have been opened. In
addition, private pharmaceutical manufacturers such as the Arab Company for
Antibiotic Industries (ACAI) and 18 other small plants are reportedly producing a
wide variety of drugs and medical supplies (Izdihar, 2007).
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The cost of health services were heavily subsidised by the Iraqi government in the
1980s, this includes providing free drugs and other hospital consumables. Currently,
medicines are imported by KIMADIA from well-known companies and then
distributed to the public sector at subsidised prices. On the other hand, the private
sector imports and distributes medicines to both the private and public sectors at
commercial prices.
1.6.2 The use of generic medicines in Iraq: A brief overview
Generic medicines are available in Iraq and are widely used in the public and private
sectors. Brand substitution has been common practice for some time due to the
shortage in brand medicines caused by the United Nation (UN) embargo, which has
been in place since 1990 (Izdihar, 2007). At present, no legislation exists regulating
brand substitution in Iraq. Iraq needs a new policy designed to regulate the
importation of generic medicine from well-known sources in order to improve the
bad image which has previously been held by patients as well as physicians and
pharmacists regarding generic medicines.
1.7 Statement of the problem
Concerns have been expressed across the globe about the perceptions of generic
medicines among physicians, pharmacists and consumers. The absence of
information with regard to generic medicines, and their dispensing, prescribing and
utilisation, is a problem in Iraq. There are no databases available to provide any basic
information, and no research studies have been conducted to highlight issues
surrounding generic medicines utilization. This study is one such attempt to address
the significant information gaps surrounding the issues of generic medicine use,
especially in issues related to prescribing and dispensing. Furthermore, no studies
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have been conducted linking the perceptions of final-year medical and pharmacy
students to the issues surrounding generic medicines prescribing and generic
medicines substitution. In order to encourage the use of generic medicines in Iraq, a
clearer understanding of the perceptions of physicians, pharmacists and consumers
regarding generic medicines is required. In addition, an understanding of the
perceptions held by final-year medical and pharmacy students is important, because
their knowledge and approaches at this stage of their careers will influence their
behaviour in the future regarding the prescription and substitution of generic
medicines.
This current research is an attempt to address this problem by means of both
qualitative and quantitative approaches.
1.8 Rationale of this study
Although generic medicines have been available over the past 20 years in the Iraqi
medicine market, the current utilisation of generic medicines and brand substitution
in Iraq is still unclear. To the best of knowledge and from through literature search,
no study has been conducted or documented in Iraq to identify consumers’ levels of
acceptance, perceptions or understanding of the use of generic medicines or brand
substitution. Indeed, the impact of generic prescribing by physicians and brand
substitution by pharmacists on patients’ understanding and safe use of their
medication is yet to be fully explored. Therefore, this study was designed to
investigate the factors affecting the use, prescription and substitution of generic
medicines among consumers, physicians, and pharmacists in Iraq. In-depth
interviews were conducted with participants from each of these groups in order to
ascertain their perceptions and understanding of generic medicines. Based on the
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outcomes of the interviews, further studies were undertaken involving final-year
medical and pharmacy students in Iraqi universities in order to evaluate their
knowledge and understanding of the issues surrounding generic medicine prescribing
and substitution, which will have an impact on the future use of generic medicines in
Iraq.
1.9 Objectives
This study consists of two main parts: the first part (using qualitative methods) is
intended to explore and gather baseline information regarding the knowledge,
attitudes and perceptions of physicians, pharmacists and consumers in Iraq towards
generic medicines. Furthermore, this study has been conducted in order to determine
the barriers faced by physicians, pharmacists and consumers regarding the use of
generic medicines.
The second part of this study adopted quantitative method to evaluate and assess the
perceptions and knowledge of the final-year medical and pharmacy students in some
Iraqi universities towards issues surrounding generic medicine use.
The specific objectives of this study are:
1. To explore the knowledge, attitudes and perceptions of physicians towards
generic medicines prescribing.
2. To evaluate the knowledge, attitudes and perceptions of pharmacists towards the
generic medicines substitution.
3. To determine the barriers faced by physicians and pharmacists with regards to
generic prescribing and dispensing.
4. To evaluate the knowledge, attitudes and perceptions of consumers towards the
use of generic medicines and
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5. To assess the knowledge and perceptions of final-year medical and pharmacy
students in Iraqi universities towards issues surrounding generic medicine use.
1.10 Significance of the study
1. This study will document the importance of the acceptance of generics in Iraq by
major stakeholder in Iraqi health delivery system.
2. This study will help to identify the issues influencing the prescribing, dispensing
and use of innovator drugs compared to generics among physicians, pharmacists and
consumers.
3. This study will provide baseline data to assist policy makers in Iraq for developing
appropriate strategies to encourage the appropriate use of generic medicines, thus
emphasising the need for a clear policy regarding generic medicines;
1.11 Overview of the thesis
Chapter 2, a thorough review of the literature which is relevant to this study was
outlined and gaps in the present literature were discussed.
Chapters 3, 4 and 5 represent the qualitative phase of the study. The respective
chapter provides information on the methodology and findings from qualitative
interviews with a purposive sample of physicians, pharmacists and consumers in
Basra, Iraq. Chapter 3 presents the findings from the interviews with physicians
about the issues involved in generic prescribing and their knowledge of
bioequivalence. Chapter 4 presents the findings from the interviews with pharmacists
regarding the issues involved with generic medicine substitution. Chapter 5 presents
the findings from interviews conducted with consumers about their perceptions of
generic medicines.
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Chapters 6, 7 and 8 describe the methodology and findings from quantitative surveys
involving final-year medical and pharmacy students in some universities in Iraq.
These surveys were designed to assess their knowledge and understanding of generic
medicines, generic prescribing and generic substitution. Chapter 6 describes the
findings of the self-administered survey conducted among final-year medical
students in some universities in Iraq in order to assess their knowledge and
understanding of generic medicines and generic prescribing. In Chapter 7, outcomes
from the self administrated survey conducted among final year pharmacy students in
some universities in Iraq about their knowledge and perceptions of generic medicines
are discussed. Chapter 8 describes a comparative analysis of the knowledge and
perceptions held by final-year medical students and final-year pharmacy students
towards generic medicines using data from similar questions posed to both groups in
their respective surveys.
Chapter 9 draws the thesis to a conclusion with an overall summary and a set of
recommendations for further research.
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CHAPTER TWO: LITERATURE REVIEW
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2.1 Physicians’ acceptance and understanding of generic medicines
Based on exhaustive literature review using standard database such as PubMed,
Scopus, Google Scholar, Embase and Science Direct, using generic medicines,
general practitioners, physicians, perception, and knowledge as keywords, there were
no studies have been conducted in Iraq to explore physicians' perceptions of generic
medicines. However, several such studies have been conducted in other developed
countries with high generic medicines utilization especially the USA and UK.
One of the earliest studies concerning generic medicines was conducted in 1980 by
Bearden et al. in The State of Alabama, USA (Mason and Bearden, 1980). This study
focused on the attitudes about, the perceptions of, the knowledge of, and the
satisfaction with generic medications and made comparisons between physicians,
pharmacists, and consumers. It also explored the silent issues affecting the
prescription of generic medicines by physicians, their dispensing by pharmacists and
their use by consumers. Mailed questionnaires were used by the researchers in this
study and responses were received from 412 physicians, 118 pharmacists and 105
consumers. All of the physicians responded that, in general, generic medicines
produced the same therapeutic effect as the original versions. Furthermore, all
physicians that participated in this study strongly agreed on that pharmacists should
only hand out drugs produced by manufacturers using GMP (good manufacturing
practice). The researchers concluded on the importance of educating physicians
earlier in their careers about the benefits and importance of generic prescribing
leading to an improved acceptance of generic drug practices (Mason and Bearden,
1980).
23
In another early study conducted in USA, Bower and Burkett (1987) reported
findings from a nationwide survey of 317 medical practitioners in family practice.
Their study reported that the percentage of respondents who have confidence in
generic drugs and prescribe them in their regular practice was 63%. Correlations
were recognised between the physicians' sources of drug information and their
prescribing patterns. Generic drugs were mostly prescribed by physicians who were
more commonly trained to be as residents, less dependent on drug companies’
representatives and were readers of the New England Journal of Medicine. Nearly
half of the respondents did not correctly differentiate all ten generic product names;
there was a strong positive relationship between recognition of the generic-named
products and the respondents' reported frequency of prescribing generic products in
general. An awareness of generic names was highest for young, residency-trained,
and board-certified family practitioners, who were more likely to read the Medical
Letter and the New England Journal of Medicine and those who relied the least on
journal advertisements (Bower and Burkett, 1987).
Shulkin (1991) carried out a study in Pennsylvania, USA. Questionnaires were
distributed anonymously to a sample of convenience containing 63 medical
practitioners in six Pennsylvania hospitals. The percentage of participants who
thought that generic and brand-name medications had the same therapeutic effects
was nearly 73 %. Although most participants reported prescribing brand-name rather
than generic products in more than 50% of their prescriptions, they did not state on
their prescriptions that the brand-name drug must be dispensed. Some differences
according to specialty were seen: for example, psychiatry residents were more likely
to prescribe brand-name drugs than surgery or internal medicine residents (Shulkin et
al., 1992).
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Banahan and Kolassa, conducted a study in the USA involving a questionnaire that
consists of five sections and 19 questions regarding attitudes, beliefs, knowledge and
experience with generic drugs that was sent to 3639 physicians nationwide (Banahan
and Kolassa, 1997). Attitudinal groups were identified by using cluster analysis and
then analysed to study the differences in beliefs, knowledge, and experience with
generic medicines. Furthermore, perception regarding the therapeutic index for 15
branded drugs and comfort in substituting those products with generic alternative
were estimated.
In the study, two groups were identified: pro-substitution and anti- substitution. The
anti-substitution group was further divided according to whether they felt more or
less influenced by exterior pressures to substitute. Less than half (43%) of the
respondents were categorised into the pro- substitution group, and they showed their
strong support for the use of generic medication. In contrast, the anti- substitution
group had strong feelings against this practice.
Physicians’ views regarding generic drugs may be influenced by their level of
knowledge of these drugs. A comparison can be conducted between two drugs
having the same active ingredient (e.g., a brand- name product and a generic product)
on the bases of the amount of variation in bioavailability permitted by the drug
regulatory authorities for each drug. This type of knowledge is significantly
important in the determination of the physicians’ intentions in using generic drugs.
When asking the participants about how much variation is permitted by the regularly
authorities (FDA), the response of “don’t know” was noted for 64% of the
participants, while only 17% answered correctly (at the time of the study, FDA
regulations generally considered two formulations to be bioequivalent if the rate and
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extent of absorption of the generic product was between 80% and 125% of that of the
brand product). The result gained from this study suggests that decisions regarding
generic drugs taken by physicians were based on inaccurate perceptions. Regarding
the therapeutic index for 15 branded drugs, the physicians in all groups identified
similar products that they believed were not suitable for substitution. (Banahan and
Kolassa, 1997).
Mcgavock conducted his study in the Republic of Ireland in 1997. A random sample
of members of the Irish College of General Practitioners received a mailed
questionnaire. This questionnaire focused on the concerns of Irish prescribers
regarding generic prescribing. This study concluded that the low rate of generic
medicine prescribing in Ireland, when compared to the rates in England and Northern
Ireland, was caused by worries expressed by the physicians regarding the reliability
and quality of the generic drugs in the market (McGavock, 1997).
A study conducted by Mott and Cline in the USA utilised a database containing
information on 6380 prescription orders for analysis. The researcher used this data to
examine the influences of the prescriber, pharmacist, insurance, patient, and drug
variables on whether or not generic drug use and generic substitution was permitted
when writing prescriptions. More than 60% of the prescription orders provided an
opportunity for generic drug use, and more than 80% of them substituted by
pharmacists and dispensed generic medicines. Physicians and pharmacists play
important roles in increasing the use of generic drugs and generic substitution.
Generally, private insurance reduces the use of generic medicines and generic
substitution. Also, prescriptions for chronic diseases have a negative correlation with
generic medicine use and generic substitution. Patient characteristics also play an
